A Post-Marketing Study of Pethidine in Indonesia: Safety Profile
Keywords:Pethidine, Meperidine, Post-marketing, Pharmacovigilance
Pethidine along with morphine and tramadol, is one of the frequently used drugs for postoperative pain management. It is important to ensure the safety of the product and ultimately the safety of the patients as users of the pethidine.
A post marketing surveillance study was conducted with a retrospective cross-sectional design using medical records and hospital pharmacy’s data in patients who were admitted to inpatient or emergency department of Dr. Sardjito General Hospital Yogyakarta between January and December 2016. The data was analyzed descriptively to estimate the proportion of adverse events (AEs) including serious adverse events (SAE).
Of the 576 patients hospitalized at the at the Dr. Sardjito General Hospital, 200 medical records were selected using consecutive sampling method. A total of 120 of the 200 subjects were found to have 245 any Adverse Events (AE) including Serious Adverse Events (SAE) following the administration of pethidine. There were 23 classifications of expected AE and 148 classifications of unexpected AE following the administration of pethidine. The duration of AE/SAE found ranged from 0 to 11 days. A total of 101 (50.5%) and 85 (42.5%) subjects experienced AE/SAE with duration <24 hours and between 1 to 2 days, respectively. The longest duration of event was pain with duration of 11 days. There were 23 types of expected AE/SAE from pethidine found in subjects, with the highest number of expected AE/SAE were weakness, vomiting, and dizziness of 24 (25%), 16 (16.8%), and 10 (10.5%), respectively. The expert panel team concluded five types of unexpected SAEs which are possible to pethidine, including respiratory acidosis, urinary tract infections, acute kidney injury, icteric, and electrolyte imbalance.
A post-marketing surveillance study provides safety profile of 50 mg / ml pethidine in Indonesia. A total of 120 of the 200 subjects who received pethidine experienced 245 Adverse Events (AEs) or Serious Adverse Events (SAEs). AEs/SAEs were divided into 23 types of expected events and 148 types of unexpected events. Few numbers of SAEs were considered possible related to the pethidine according to expert panel review.
Keywords: pethidine, meperidine, post-marketing, pharmacovigilance
Plum Analytics Artifact Widget Block
Lee MC, Abrahams M. Pain and analgesics. In: Clinical Pharmacology. 11th ed., Vol. 14. Churchill Livingstone, London Elsevier Ltd.; 2012. p. 278-94. Available from: https://doi.org/10.1016/B978-0-7020-4084-9.00057-4 [Last accessed on 2021 Nov 01]. DOI: https://doi.org/10.1016/B978-0-7020-4084-9.00057-4
O’Connor A, Schug SA, Cardwell H. A comparison of the efficacy and safety of Morphine and Pethidine as analgesia for suspected renal colic in the emergency setting. J Accid Emerg Med. 2000;17(4):261-4. https://doi.org/10.1136/emj.17.4.261 PMid:10921813 DOI: https://doi.org/10.1136/emj.17.4.261
Fisher J, Ganellin CR. Analogue-Based Drug Discovery. Research Triangle Park: Chemistry International - Newsmagazine for IUPAC: 2010. p. 12-5.
Ngan Kee WD. Intrathecal pethidine: Pharmacology and clinical applications. Anaesth Intensive Care. 1998;26(2):137-46. https://doi.org/10.1177/0310057X9802600202 PMid:9564390 DOI: https://doi.org/10.1177/0310057X9802600202
Macintyre P, Bochner F, Wiltshire S, Molloy A. Does Pethidine still have a place in therapy? Aust Prescr. 2002;25:79-80. DOI: https://doi.org/10.18773/austprescr.2002.069
Latta KS, Ginsberg B, Barkin RL. Meperidine: A critical review. Am J Ther. 2002;9(1):53-68. https://doi.org/10.1097/00045391-200201000-00010 PMid:11782820 DOI: https://doi.org/10.1097/00045391-200201000-00010
Seifert CF, Kennedy S. Meperidine is alive and well in the new millennium: Evaluation of meperidine usage patterns and frequency of adverse drug reactions. Pharmacotherapy. 2004;24(6):776-83. https://doi.org/10.1592/phco.24.8.776.36066 PMid:15222668 DOI: https://doi.org/10.1592/phco.24.8.776.36066
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45. https://doi.org/10.1038/clpt.1981.154 PMid:7249508 DOI: https://doi.org/10.1038/clpt.1981.154
Food and Drug Administration (FDA). Demerol Injection Prescribing Information; 2007. p. 37620. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021171s024s025lbl.pdf. [Last accessed on 2021 Nov 01].
Friesen KJ, Falk J, Bugden S. The safety of meperidine prescribing in older adults: A longitudinal population-based study. BMC Geriatr. 2016;16(1):1-7. Available from: https://doi.org/10.1186/s12877-016-0275-5 [Last accessed on 2021 Nov 01]. DOI: https://doi.org/10.1186/s12877-016-0275-5
Radnay P, Boradman E, Mankikar D, Duncalf D. The effects of equi-analgesic doses of fentanyl, morphine and pentazocine on common bile duct pressure. Anesthetist. 1980;29(1):26-9. PMid:6104938
Mildh LH, Leino KA, Kirvelä OA. Effects of tramadol and meperidine on respiration, plasma catecholamine concentrations, and hemodynamics. J Clin Anesth. 1999;11(4):310-6. https://doi.org/10.1016/s0952-8180(99)00047-1 PMid:10470633 DOI: https://doi.org/10.1016/S0952-8180(99)00047-1
Hoseinkhan Z, Behzadi M. Morphine, pethidine and fentanyl in post-operative shivering control: A randomized clinical trial. Tehran Univ Med J TUMS Publ. 2006;64(12):57-63.
Dabir S, Jahandideh M, Abbasinazari M, Kouzekanani H, Parsa T, Radpay B. The efficacy of a single dose of pethidine, fentanyl, and morphine in treating postanesthesia shivering. Pak J Pharm Sci. 2011;24(4):513-7. PMid:21959813
Alfonsi P, Hongnat JM, Lebrault C, Chauvin M. The effects of pethidine, fentanyl and lignocaine on postanaesthetic shivering. Anaesthesia. 1995;50(3):214-7. https://doi.org/10.1111/j.1365-2044.1995.tb04559.x PMid:7717486 DOI: https://doi.org/10.1111/j.1365-2044.1995.tb04559.x
Meperidine Interaction. Available from: https://www.drugs.com/drug-interactions/meperidine.html. [Last accessed on 2021 Nov 01].
How to Cite
Copyright (c) 2022 Jarir At Thobari, Jonathan Haposan, Muhammad Nurwahidin, Lukman Ade Chandra, Asri Riswiyanti, Djayanti Sari, Yunita Widyastuti, Sudarwanti Sudarwanti, Nastia Hidayati, Rianiasa Karunia Dewi, Rita Purnamasari, Dyah Juliana Pudjiati (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.